Arrowhead Subsidiary, Calando Pharmaceuticals, to Present Preclinical Results of Non-Human Primate Studies at Oligonucleotide Therapeutic Society Annual Meeting.PASADENA, Calif. -- Arrowhead Research Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ARWR) announced today that Dr. Jeremy Heidel, Chief Scientific Officer of Calando ca·lan·do adv. & adj. Music With a gradual decrease in volume and often tempo. Used chiefly as a direction. [Italian, present participle of calare, to slacken Pharmaceuticals, Inc., a majority-owned subsidiary majority-owned subsidiary A firm in which more than 50% of outstanding voting stock is owned by the parent company. of Arrowhead, will present at the Second Annual Meeting of the Oligonucleotide Therapeutic Society on Friday, October 20, 2006 at 5:00 p.m. ET, at The Rockefeller University Rockefeller University, philanthropic organization in New York City, founded 1901 as the Rockefeller Institute for Medical Research by John D. Rockefeller for furthering medical science and its allied subjects and to make knowledge of these subjects available to the in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Dr. Heidel's presentation is entitled "Systemic delivery of siRNA via targeted nanoparticles." During his presentation, Dr. Heidel will detail Calando's lead siRNA-containing therapeutic formulation, CALAA-01, including target gene and indication. He will also present pre-clinical results demonstrating the efficacy of the siRNA, as well as preliminary data from rodent and non-human primate studies of Calando's siRNA-containing nanoparticles, which are prepared using Calando's proprietary cyclodextrin-containing polymer delivery technology. About Arrowhead Research Corporation Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials Semiconductor materials are insulators at absolute zero temperature that conduct electricity in a limited way at room temperature (see also Semiconductor). The defining property of a semiconductor material is that it can be doped with impurities that alter its electronic properties . About Calando Pharmaceuticals, Inc. Calando Pharmaceuticals, Inc. (www.calandopharma.com), a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), is using its proprietary technologies in targeted polymeric delivery systems and siRNA design to design and create new, targeted siRNA therapeutics. The company is pursuing this goal through its internal research and development and also through collaborations and partnerships with pharmaceutical and biotechnology companies. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion